Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
3-V Bioscience-2640 · 1 trial · 1 indication
Subject undergoes a stable isotope infusion followed by blood draws. Plasma lipid samples are measured by gas chromatography/mass spectrophotometry.
| Arm | Type | Description |
|---|---|---|
| 3-V Bioscience-2640 | EXPERIMENTAL | Subjects will take a singly daily dose of 3-V Bioscience-2640 before bedtime or 22:30, whichever comes first, for 10 days. |
| Name | Type | Description |
|---|---|---|
| 3-V Bioscience-2640 | DRUG | Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days. |
Inclusion Criteria: 1. Men with characteristics of metabolic syndrome 1. Waist circumference greater than 40 in (102 cm) 2. Plasma TG greater than 150 mg/dL 3. HDL cholesterol less than 40 mg/dL 4. Blood pressure greater than or equal to 130/85 mmHg 5. Fasting plasma glucose greater...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| NewAmsterdam Pharma Company N.V. | NAMS | 1 | PHASE3 | obicetrapib, ezetimibe daily |
| Veru Inc | VERU | 1 | PHASE2 | Enobosarm, Semaglutide weekly |
| Collegium Pharmaceutical, Inc. | COLL | 1 | PHASE3 | Empagliflozin |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | - | Undisclosed |
| Abbott Laboratories | ABT | 1 | - | Undisclosed |
| Elevance Health, Inc. | ELV | 1 | N/A | Undisclosed |
3-V Bioscience-2640 is an investigational small molecule being developed for the treatment of Metabolic Syndrome. It is a Phase 1 drug candidate that has been evaluated in a completed clinical trial in the United States. The drug is not approved and remains in clinical development.
3-V Bioscience-2640 is being developed by Sagimet Biosciences Inc., which trades under the ticker SGMT. The company is conducting clinical research on this small molecule for Metabolic Syndrome. As of the available data, the drug is in Phase 1 development.
3-V Bioscience-2640 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized, open-label study. The drug is investigational and has not been approved by regulatory authorities.
3-V Bioscience-2640 has been studied in one completed clinical trial, identified as NCT02948569. This Phase 1 study evaluated the drug's effect on reducing de novo lipogenesis in subjects with characteristics of Metabolic Syndrome. The trial enrolled 12 male participants in the United States.
No alternative names for 3-V Bioscience-2640 have been disclosed. The drug is identified by this name in clinical trial records and is being developed by Sagimet Biosciences. It is a distinct investigational small molecule for Metabolic Syndrome.